As of October 8, 2026, the U.S. oral GLP-1 weight-loss race has two approved medicines: Novo Nordisk’s once-daily Wegovy pill (semaglutide) and Eli Lilly’s once-daily Foundayo (orforglipron). Pfizer’s danuglipron is no longer in development. Trial results suggest both approved pills can produce substantial weight loss, but the studies differ too much to declare a reliable winner from their headline percentages alone.
What happened to Pfizer’s weight-loss pill?
Pfizer discontinued development of danuglipron on April 14, 2025, after reviewing clinical data and receiving input from regulators. In its announcement, Pfizer said one participant in a dose-optimization study had experienced potential drug-induced liver injury without symptoms; the condition resolved after the medicine was stopped. Pfizer also said the frequency of liver-enzyme elevations in its safety database of more than 1,400 participants was in line with approved medicines in the class. The company did not describe the single case as the sole reason for ending development.
Pfizer’s decision removed one candidate from the competition, but it did not end the effort to make GLP-1 treatment available as a pill. The U.S. market subsequently gained oral versions of medicines from Novo Nordisk and Lilly.
Which oral GLP-1 weight-loss medicines are approved in the U.S.?
The milestones below are U.S.-specific. They do not establish approval or availability in other countries.
#1 Best Overall
| Date | Milestone |
|---|---|
| April 14, 2025 | Pfizer announced that it was discontinuing danuglipron development after reviewing clinical data and regulator input. |
| September 16, 2025 | Lilly reported Phase 3 ATTAIN-1 results for investigational orforglipron. |
| December 22, 2025 | Novo Nordisk announced U.S. FDA approval of oral Wegovy (semaglutide) 25 mg, describing it as the first oral GLP-1 medicine approved for obesity in the U.S. |
| April 1, 2026 | The FDA approved Foundayo (orforglipron) for chronic weight management in eligible U.S. adults. |
| April 9, 2026 | Lilly announced Foundayo’s U.S. availability through LillyDirect and telehealth providers, with retail pharmacy availability expanding that day. |
The FDA describes Foundayo’s indication as use with a reduced-calorie diet and increased physical activity for adults with obesity, or adults with overweight and at least one weight-related comorbid condition. Novo Nordisk’s announcement also describes an indication for reducing major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease.
Wegovy pill vs. Foundayo: what do the trials show?
The most prominent weight-loss results come from separate placebo-controlled trials, not a direct comparison of the two obesity-dose pills. OASIS 4 studied oral semaglutide; ATTAIN-1 studied orforglipron. Their populations, durations and statistical methods differ, so the percentages should be read in context rather than ranked as if they came from one trial.
| Medicine and trial | Trial population and duration | Reported mean weight loss | Source and interpretation |
|---|---|---|---|
| Oral Wegovy (semaglutide 25 mg), OASIS 4 | 307 adults with obesity, or overweight plus a weight-related comorbidity; participants with diabetes were excluded. 64 weeks. | 16.6% in an analysis modeled as if participants stayed on treatment; 13.6% regardless of whether participants stayed on treatment. Placebo: 2.7% and 2.4%, respectively. | Novo Nordisk’s 2025 announcement. The two active-treatment percentages use different estimands, not alternative readings of one identical analysis. |
| Foundayo (orforglipron), ATTAIN-1 | 3,127 participants randomized; adults with obesity, or overweight plus selected weight-related comorbidities, without diabetes. 72 weeks. | At the highest dose, 12.4% among participants who stayed on treatment; 11.1% regardless of trial completion. Placebo: 0.9% and 2.1%, respectively. | Lilly’s 2026 report. The figures use different estimands and should be kept with their duration and population. |
These figures are trial results reported by the manufacturers, not a head-to-head test and not a promise of an individual result. Differences in study duration, enrolled participants, treatment continuation and statistical analysis make a simple comparison misleading. The percentages also describe average changes in trial groups; they do not predict how much any one person will lose.
Does the head-to-head trial settle the comparison?
No. Lilly’s ACHIEVE-3 was a 52-week Phase 3 study of 1,698 adults with type 2 diabetes whose blood sugar was inadequately controlled with metformin. It compared orforglipron at 12 mg and 36 mg with oral semaglutide at 7 mg and 14 mg—diabetes-treatment doses in a diabetes population, not Foundayo versus the obesity-dose Wegovy pill in an obesity population.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Under ACHIEVE-3’s efficacy estimand, Lilly reported mean weight changes at week 52 of 9.2% for orforglipron 36 mg and 5.3% for oral semaglutide 14 mg. That is useful evidence about the treatments in the study’s specific diabetes setting; it does not establish which approved obesity pill produces greater weight loss.
How do the pills differ in use and safety?
Administration
Both products are once-daily oral medicines. The FDA says Foundayo does not need to be taken on an empty stomach, and Lilly says it has no food or water restrictions. The information summarized here does not reproduce the complete dosing and missed-dose instructions for either medicine; patients should follow the current prescribing information for their product.
Side effects and warnings
The FDA lists nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, fatigue, reflux, gas and hair loss among Foundayo’s side effects. Its approval information also identifies warnings and precautions involving pancreatitis, severe gastrointestinal reactions, acute kidney injury from volume depletion, hypoglycemia, hypersensitivity, diabetic retinopathy in people with type 2 diabetes, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation. FDA says Foundayo should not be combined with another GLP-1 receptor agonist.
Novo Nordisk’s OASIS 4 announcement lists nausea, diarrhea and vomiting among common adverse reactions with the Wegovy pill, with reactions described as similar to those seen in Wegovy injection trials. These separate descriptions do not establish that one medicine is safer or easier to tolerate than the other. For a complete and current account of contraindications, warnings and interactions, consult each medicine’s current U.S. prescribing information with a clinician.
What the race means for patients and the market
The shift from Pfizer’s discontinued candidate to two FDA-approved oral options changes the treatment landscape, but it does not make the medicines interchangeable or turn clinical-trial averages into a consumer price comparison. Both are prescription medicines, and availability routes, coverage, out-of-pocket costs and country-specific approval status can change. The trial results answer questions about average weight change under defined study conditions; they do not establish what a particular patient will pay or which treatment a clinician should choose.
For a fair comparison, check the indication and current label, the trial population and duration, and whether a quoted result assumes participants stayed on treatment. A clinician can assess whether either medicine is appropriate in light of an individual’s health history and other medicines.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
